Skip to main content

Month: July 2021

Replace Silicon IGBTs with Industry’s Most Rugged Silicon Carbide Power Solutions Now Available at 1700V

Silicon carbide portfolio with 1700V MOSFET die, discrete and power module devices extend designers’ options for efficiency, power density CHANDLER, Ariz., July 27, 2021 (GLOBE NEWSWIRE) — Today’s energy-efficient electric charging systems powering commercial vehicle propulsion, as well as auxiliary power systems, solar inverters, solid-state transformers and other transportation and industrial applications all rely on high-voltage switching power devices. To meet these requirements, Microchip Technology Inc. (Nasdaq: MCHP) today announced the expansion of its silicon carbide portfolio with a family of high-efficiency, high-reliability 1700V silicon carbide MOSFET die, discrete and power modules. Microchip’s 1700V silicon carbide technology is an alternative to silicon IGBTs. The earlier technology required designers to compromise...

Continue reading

CV Sciences, Inc. Receives NutraIngredients-USA 2021 Product of the Year: Immune Support Award

CV™ DefenseCV Sciences Receives NutraIngredients-USA’s 2021 Product of the Year: Immune Support Award for its CV™ Defense product.SAN DIEGO, July 27, 2021 (GLOBE NEWSWIRE) — CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, announced today that it received NutraIngredients-USA’s 2021 Product of the Year: Immune Support Award for its CV™ Defense product. Focusing on true innovation, long-term market success and cutting-edge research, the NutraIngredients-USA Awards honor the best and brightest in ingredients, finished products, companies, people, and initiatives in the nutrition and dietary supplements industry. CV™ Defense was created with a specific intent — to fortify daily immune health. The active...

Continue reading

Cidara Therapeutics to Present New Data for Rezafungin at the International Society for Human and Animal Mycology (ISHAM) Asia Congress

SAN DIEGO, July 27, 2021 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will present clinical and pre-clinical data, including updated analyses from the Phase 2 STRIVE study and an in vitro evaluation of rezafungin activity against Candida and Aspergillus spp. isolates collected in Asia-Pacific countries, in two presentations at the International Society for Human and Animal Mycology (ISHAM) Asia Congress taking place virtually from August 6-8, 2021. Rezafungin is a novel once-weekly echinocandin currently being studied in Phase 3 trials for the treatment and prevention of serious fungal infections in critically ill patients. ISHAM Asia...

Continue reading

City of Walla Walla, Washington Orders Beam Global EV ARC™ Off-Grid EV Charging System

Rapidly deployed sustainable EV charging infrastructure to kick off fleet electrification initiative SAN DIEGO, July 27, 2021 (GLOBE NEWSWIRE) — Beam Global, (Nasdaq: BEEM, BEEMW), the leading provider of innovative sustainable technology for electric vehicle (EV) charging, outdoor media and energy security, announced that the City of Walla Walla in Washington State has ordered its first EV ARC™ solar-powered EV charging system to power two fully electric city fleet vehicles. The system also serves the City’s emergency preparedness and energy resiliency programs. Walla Walla’s EV ARC™ is equipped with a ChargePoint Dual Port charger and an emergency power panel. The EV ARC™ generates and stores its own electricity and delivers that electricity to power City fleet EVs and first responders, day or night, and during inclement weather...

Continue reading

Rhythm Pharmaceuticals to Report Second Quarter 2021 Financial Results on Tuesday, August 3, 2021

BOSTON, July 27, 2021 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, August 3, 2021 to report its second quarter 2021 financial results and provide a corporate update. To access the live conference call, please dial (844) 498-0570 (domestic) or (409) 983-9726 (international), and refer to conference ID 6776764. A webcast of the call will also be available under “Events & Presentations” in the Investor Relations section of the Rhythm website at ir.rhythmtx.com. The archived webcast will be available on Rhythm’s website approximately two hours after the conference call and will be available...

Continue reading

Nanox to Announce Second Quarter 2021 Financial and Operating Results on Tuesday, August 10, 2021

Management to host conference call and webcast at 8:30 AM ET on that day NEVE ILAN, Israel, July 27, 2021 (GLOBE NEWSWIRE) — NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, announces that it will release its second quarter 2021 financial and operating results for the period ended June 30, 2021 on Tuesday, August 10, 2021 prior to the start of trading. Management will host a conference call and webcast at 8:30am ET on that day. Conference call and webcast details Tuesday, August 10, 2021 @ 8:30am ETInvestor domestic dial-in:   855-327-6837Investor international dial-in:   631-891-4304Conference ID: 10015901Webcast link: http://public.viavid.com/index.php?id=146006 About Nanox: Nanox, founded by the serial entrepreneur Ran Poliakine, is an Israeli corporation that is...

Continue reading

StepStone Group to Announce First Quarter Fiscal 2022 Results on August 10, 2021

NEW YORK, July 27, 2021 (GLOBE NEWSWIRE) — StepStone Group Inc. (Nasdaq: STEP) today announced that the Company will release its results for the quarter ending June 30, 2021 after the market closes on Tuesday, August 10, 2021. This represents results for the first quarter of the fiscal year ending March 31, 2022. Webcast and Earnings Conference Call Management will host a webcast and conference call on Tuesday, August 10, 2021 at 5:00 pm ET to discuss the Company’s results for the first quarter of the fiscal year ending March 31, 2022. The conference call will also be made available in the Shareholders section of the Company’s website at https://shareholders.stepstonegroup.com. To listen to a live broadcast, go to the site at least 15 minutes prior to the scheduled start time in order to register. The conference call can...

Continue reading

OptimizeRx Sets Second Quarter Fiscal 2021 Conference Call for Wednesday, August 4 at 4:30 p.m. ET

ROCHESTER, Mich., July 27, 2021 (GLOBE NEWSWIRE) — OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, physicians and patients, will hold a conference call on Wednesday, August 4, 2021, at 4:30 p.m. Eastern time to discuss its results for the second quarter, ended June 30, 2021. The financial results will be issued in a press release prior to the call. OptimizeRx management will host the call, followed by a question and answer period. Conference Call Information:Date: Wednesday, August 4, 2021Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time)Webcast: http://public.viavid.com/index.php?id=146009Toll Free Number: 800-430-8332International Number: 323-289-6576Conference ID: 2901587Please call the conference telephone number or log on to...

Continue reading

BetterLife Receives Approval to Conduct COVID-19 Randomized Placebo-Controlled Trial with Pontificia Universidad Católica de Chile

VANCOUVER, British Columbia, July 27, 2021 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU) today announced that its wholly owned subsidiary, Altum Pharmaceuticals Inc. (“Altum”), and Pontificia Universidad Católica de Chile have obtained approval from the Instituto de Salud Publica de Chile to conduct their planned randomized placebo-controlled trial (“IN2COVID”) in COVID-19 patients. The trial, set to start in early August, tests BetterLife’s proprietary inhaled interferon alpha-2b (“IFN-a2b”) product, AP-003. BetterLife’s Chief Executive Officer, Dr. Ahmad Doroudian, commented, “We are excited to initiate this trial of AP-003 in COVID-19 patients in collaboration with the Escuela de Medicina (school of medicine) at Pontificia Universidad Católica de Chile....

Continue reading

Moving iMage Technologies’ Frank Tees Named President of International Cinema Technology Association (ICTA)

Frank TeesMoving iMage Technologies’ Frank Tees named President of International Cinema Technology Association (ICTA)FOUNTAIN VALLEY, Calif., July 27, 2021 (GLOBE NEWSWIRE) — Moving iMage Technologies (NYSE: MITQ) (“MiT”), a leading digital cinema company that designs, manufactures, integrates, installs and distributes a full suite of proprietary and custom-designed equipment, announced today that Frank Tees, MiT’s Vice President, Technical Sales Support, has been named President of the International Cinema Technology Association (ICTA), the cinema industry’s trade association whose members are widely recognized as the experts within the industry on theatre equipment and services. Tees will continue in his position at MiT. He had served as a Vice President of ICTA for the past three years and has served on...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.